Lokeshwar Nilesh, Kumar Lalit, Kumari Mamta
Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India.
Leuk Lymphoma. 2005 May;46(5):781-4. doi: 10.1080/10428190500046778.
Imatinib mesylate, a signal transduction inhibitor molecule, has been introduced in the treatment of chronic myelogenous leukemia (CML) since May 2001. By its unique mechanism of action, the drug has revolutionized the management of chronic phase CML. The drug is generally well tolerated. A number of hematological and non-hematological side-effects have been reported. Fatal bone marrow (BM) aplasia has rarely been reported. A 46-year-old women with chronic phase CML was treated with imatinib. Six weeks later she developed severe pancytopenia associated with fever, chest infection and bleeding. A BM biopsy revealed hypoplasia (BM cellularity < 5%). She died of pulmonary mucormycosis. CML patients on imatinib therapy need close monitoring. Those pre-treated with busulfan and interferon-alpha may be at a higher risk of developing BM aplasia.
甲磺酸伊马替尼是一种信号转导抑制剂分子，自2001年5月起被用于治疗慢性粒细胞白血病（CML）。凭借其独特的作用机制，该药彻底改变了慢性期CML的治疗方式。该药一般耐受性良好。已报告了一些血液学和非血液学副作用。致命的骨髓再生障碍很少被报告。一名46岁的慢性期CML女性患者接受了伊马替尼治疗。六周后，她出现了严重的全血细胞减少，并伴有发热、肺部感染和出血。骨髓活检显示骨髓发育不全（骨髓细胞密度<5%）。她死于肺毛霉菌病。接受伊马替尼治疗的CML患者需要密切监测。那些曾接受白消安和α干扰素预处理的患者发生骨髓再生障碍的风险可能更高。
